前列腺癌预测模型在MRI与经会阴活检人群中的外部验证比较
本研究在澳大利亚两个中心接受经会阴活检的797例患者中,对373例有完整数据的患者外部验证并比较了ERSPC-RC3/4、PBCG-RC和van Leeuwen模型预测高级别前列腺癌的性能。结果显示van Leeuwen模型AUC最高(0.81),ERSPC-RC3/4次之(0.79),PBCG-RC较差(0.68),均优于单独PSA(0.58)。ERSPC-RC3/4在中危风险范围校准最佳,van Leeuwen模型在低危范围校准最佳,且van Leeuwen模型从10%风险起净获益最大。结论推荐澳大利亚泌尿外科医生在临床中使用ERSPC-RC3/4进行风险预测。
要点
- van Leeuwen模型区分度最佳(AUC 0.81),ERSPC-RC3/4次之(0.79),PBCG-RC较差(0.68)。
- ERSPC-RC3/4在中危风险范围10-40%校准最佳,van Leeuwen模型在低危范围0-10%校准最佳。
- van Leeuwen模型从10%风险起净获益最大,ERSPC-RC3/4紧随其后。
核心结论
- ERSPC-RC3/4在澳大利亚经会阴活检人群中表现良好,与van Leeuwen模型在区分度、校准和净获益方面相当,推荐临床使用ERSPC-RC3/4。
研究设计与样本
- 回顾性研究,纳入两个中心797例接受经会阴活检的患者,其中373例有数据测试所有三种风险计算器。
主要发现
- 检测高级别前列腺癌(ISUP Grade Group >1)的AUC:ERSPC-RC3/4为0.79(95%CI 0.74-0.84),van Leeuwen模型为0.81(95%CI 0.77-0.86),PBCG-RC为0.68(95%CI 0.63-0.74),单独PSA为0.58(95%CI 0.52-0.65)。
- ERSPC-RC3/4在10-40%中等风险范围校准最佳,van Leeuwen模型在0-10%低风险范围校准最佳。
- van Leeuwen模型从10%风险起净获益最大,ERSPC-RC3/4紧随其后,PBCG-RC再次之。
关键数值与推荐
- 高级别前列腺癌定义为ISUP Grade Group >1。
- 区分度评估使用受试者工作特征曲线下面积(AUC),校准使用数值和图形摘要,净获益使用决策曲线分析。
临床怎么用
- 澳大利亚泌尿外科医生可使用ERSPC-RC3/4预测接受经会阴活检男性的前列腺癌风险,因其在线平台易用且性能良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To externally validate and compare the performance of the European Randomized Study of Screening for Prostate Cancer risk calculator 3/4 (ERSPC-RC3/4), the Prostate Biopsy Collaborative Group risk calculator (PBCG-RC) and the van Leeuwen model to determine which prediction model would perform the best in a contemporary Australian cohort undergoing transperineal (TP) biopsy. MATERIALS AND METHODS: A retrospective review identified all patients undergoing TP biopsy across two centres. Of the 797 patients identified, 373 had the data required to test all three risk calculators. The probability of high-grade prostate cancer, defined as International Society of Urological Pathology Grade Group >1, was calculated for each patient. For each prediction model discrimination was assessed using area under the receiver-operating characteristic curve (AUC), calibration using numerical and graphical summaries, and net benefit using decision curve analysis. RESULTS: Assessment of model discrimination for detecting high-grade prostate cancer showed AUCs of 0.79 (95% confidence interval [CI] 0.74-0.84) for the ERSPC-RC3/4, 0.81 (95% CI 0.77-0.86) for the van Leeuwen model, and 0.68 (95% CI 0.63-0.74) for the PBCG-RC, compared to 0.58 (95% CI 0.52-0.65) for prostate-specific antigen alone. The ERSPC-RC3/4 was the best calibrated in the moderate-risk range of 10-40%, whilst the van Leeuwen model was the best calibrated in the low-risk range of 0-10%. The van Leeuwen model demonstrated the greatest net benefit from 10% risk onwards, followed closely by the ERSPC-RC3/4 and then the PBCG-RC. CONCLUSION: The ERPSC-RC3/4 demonstrated good performance and was comparable to the van Leeuwen model with regard to discrimination, calibration and net benefit for an Australian population undergoing TP prostate biopsy. It is one of the most accessible risk calculators with an easy-to-use online platform, therefore, we recommend that Australian urologists use the ERSPC-RC3/4 to predict risk in the clinical setting.
引用
- Doan P, Graham P, Lahoud J, et al. A comparison of prostate cancer prediction models in men undergoing both magnetic resonance imaging and transperineal biopsy: Are the models still relevant? BJU Int. 2021. PMID: 34374190. doi:10.1111/bju.15554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。